Rapamycin impairs endothelial cell function in human internal thoracic arteries by unknown
EUROPEAN JOURNAL 
OF MEDICAL RESEARCH
Reineke et al. European Journal of Medical Research  (2015) 20:59 
DOI 10.1186/s40001-015-0150-4RESEARCH Open AccessRapamycin impairs endothelial cell function
in human internal thoracic arteries
David C. Reineke1, Else Müller-Schweinitzer2,3, Bernhard Winkler1,3, Donatina Kunz2,3, Moritz A. Konerding4,
Thomas Grussenmeyer2,3, Thierry P. Carrel1, Friedrich S. Eckstein2,3 and Martin T.R. Grapow2,3*Abstract
Background: Definitive fate of the coronary endothelium after implantation of a drug-eluting stent remains unclear,
but evidence has accumulated that treatment with rapamycin-eluting stents impairs endothelial function in human
coronary arteries. The aim of our study was to demonstrate this phenomenon on functional, morphological and
biochemical level in human internal thoracic arteries (ITA) serving as coronary artery model.
Methods: After exposure to rapamycin for 20 h, functional activity of ITA rings was investigated using the organ
bath technique. Morphological analysis was performed by scanning electron microscopy and evaluated by two
independent observers in blinded fashion. For measurement of endothelial nitric oxide synthase (eNOS) release,
mammalian target of rapamycin (mTOR) and protein kinase B (PKB) (Akt) activation, Western blotting on human
mammary epithelial cells-1 and on ITA homogenates was performed.
Results: Comparison of the acetylcholine-induced relaxation revealed a significant concentration-dependent decrease
to 66 ± 7 % and 36 ± 7 % (mean ± SEM) after 20-h incubation with 1 and 10 μM rapamycin. Electron microscopic
evaluation of the endothelial layer showed no differences between controls and samples exposed to 10 μM rapamycin.
Western blots after 20-h incubation with rapamycin (10 nM–1 μM) revealed a significant and concentration-dependent
reduction of p (Ser 1177)-eNOS (down to 38 ± 8 %) in human mammary epithelial cells (Hmec)-1. Furthermore, 1 μM
rapamycin significantly reduced activation of p (Ser2481)-mTOR (58 ± 11 %), p (Ser2481)-mTOR (23 ± 4 %) and p
(Ser473)-Akt (38 ± 6 %) in ITA homogenates leaving Akt protein levels unchanged.
Conclusions: The present data suggests that 20-h exposure of ITA rings to rapamycin reduces endothelium-mediated
relaxation through down-regulation of Akt-phosphorylation via the mTOR signalling axis within the ITA tissue without
injuring the endothelial cell layer.
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The use of drug-eluting stents (DES) has markedly re-
duced the risk of restenosis after coronary angioplasty as
compared to bare metal stents. Rapamycin or one of its
derivates is the most widely employed drug in DES. It
suppresses the growth of neo-intimal vascular smooth
muscle cells by inhibiting the mammalian target of
rapamycin (mTOR), a serine/threonine kinase that
plays an important role in the regulation of cell prolif-
eration [1–3]. However, with the frequency of late stent* Correspondence: martin.grapow@usb.ch
2Department of Cardiac Surgery, University Hospital Basel, Spitalstrasse 21,
Basel CH-4031, Switzerland
3Department of Biomedicine, University Basel, Basel CH-4031, Switzerland
Full list of author information is available at the end of the article
© 2015 Reineke et al. This is an Open Access
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/thrombosis increasing considerably after discontinu-
ation of the dual antiplatelet therapy, concerns have re-
cently arisen regarding adverse effects in some patients.
Early pharmacological experiments with rat aortic tis-
sue comparing different immunosuppressive substances
and their influence on endothelial function revealed bene-
ficial effects of rapamycin. In contrast to cyclosporine-C
and FK-506, both negatively influencing endothelial func-
tion, rapamycin even potentiated endothelium-dependent
relaxation in these tissues [4, 5]. Furthermore, it has been
shown in Lewis rats that besides preservation of endothe-
lial function, sensitivity to vasospasm is not increased and
normal levels of endothelial nitric oxide synthase (eNOS)
protein expression are maintained [6].article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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rapamycin depresses endothelium-dependent relaxation
in pig coronary arteries in vitro [7]. These data are
largely confirmed with paclitaxel-eluting stents. Pacli-
taxel is a mitotic inhibitor and was initially used as a
chemotherapeutic agent. For the treatment of restenosis,
its antiproliferative effect is of value by inhibiting neo-
intimal growth within the coated stent resulting in
scared tissue [8].
First functional data on human coronary arteries was
reported by Togni showing that exercise-induced coron-
ary vasomotion is totally different in segments proximal
and distal to rapamycin and paclitaxel-eluting stents
when evaluated 6 months after deployment [9]. While
patients who had received bare-metal stents or reference
vessels without stents revealed normal exercise-induced
vasodilatation, patients with DES clearly demonstrated
paradoxical vasoconstriction around the vessel segments
of rapamycin and paclitaxel-eluting stents. By contrast,
vasodilator response to nitroglycerin was maintained,
suggesting a drug-induced endothelial dysfunction as the
underlying mechanism [9, 10].
Our goal was, therefore, to investigate in a human ar-
tery model whether exposure of human internal thoracic
arteries to rapamycin in vitro modifies vascular function
and/or reduces nitric oxide production/release, thus
studying directly the physiological and morphological in-
fluence of rapamycin on the human endothelium.
Methods
Organ bath experiments
Human internal thoracic arteries (ITA; 10–20 mm long,
inner diameter 1–2 mm) were taken during bypass sur-
gery at the beginning of the operation before induction
of the cardiopulmonary circuit and after obtainingTable 1 Clinical profile, risk factors and preoperative therapy of the
Organ bath on ITA rings West
NA and Ach m-TO
Age (years) 64 (56–84) 62 (5
Number of patients (n) 21 6
n (%) n (%)
Smokers 6 (29) 2 (33
Hypercholesterinemia 13 (62) 2 (33
Arterial hypertension 11 (52) 4 (67
Diabetes mellitus 2 (10) 0
Aspirin 12 (57) 5 (83
Statine 14 (67) 6 (10
Beta-blocker 14 (67) 4 (67
ACE inhibitors 4 (19) 2 (33
Calcium entry blockers 1 (5) 0approval from the local ethical committee with patients’
informed consent. The ethics committee Basel county of
the University of Basel Switzerland (Spitalstrasse 12,
4031 Basel, Basel, Switzerland) approved the study prior
to conduction, and all patients were interviewed prior to
the operation and had to give their consent in written
form. Arteries from a total of 21 patients (19 males, 2 fe-
males) with a mean age of 64 years (range 56–84) were
employed. Comprehensive patients’ details are presented
in Table 1. The preparations were placed into RPMI cul-
ture medium or modified Krebs-Henseleit (KH) solution
(composition mM: NaCl 118, KCl 4.7, MgSO4 1.2, CaCl2
1.25, KH2PO4 1.2, NaHCO3 25, glucose 11, EDTA 0.03)
at room temperature and directly transported to the la-
boratory. The vessels were cleaned from loose connect-
ive tissue avoiding any traction or tension on the
material using a microscope and microvascular instru-
ments, cut into rings (about 2–3 mm long), mounted be-
tween two hooks of stainless steel wire (diameter 0.5
mm), suspended in 10-ml organ baths containing KH
solution at 37 °C and gassed continuously with 5 % CO2
in oxygen (Fig. 1). Changes in the tone of the prepara-
tions were recorded isometrically under a resting tension
of 1 g with electromechanical transducers (Statham
model UC 3, Gould Inc., Oxnard, CA, USA) and a po-
tentiometric recorder (Servorec 460, Morawtz Inc.,
Germany). At the beginning of the experiments, the
rings were stretched to an initial tension of about 1.5 g
and allowed to relax and equilibrate for about 2–3 h in
the bathing medium. During this time, the baseline ten-
sion of the rings was readjusted to 1 g if required.
Thereafter, the rings were contracted with noradren-
aline (NA; 1 μM). When the NA effect was levelling off,
endothelial function was tested by adding acetylcholine
(ACh; 1 μM). Only rings showing a minimum of 40 %patients
ern blot on ITA homogenates
R p-mTOR Akt p-Akt
6–68) 64 (56–71) 68 (54–81) 68 (54–81)
6 19 24
n (%) n (%) n (%)
) 2 (33) 5 (26) 9 (38)
) 2 (33) 11 (58) 17 (71)
) 5 (83) 14 (74) 16 (67)
1 (17) 9 (47) 9 (38)
) 6 (100) 17 (89) 20 (83)
0) 6 (100) 15 (79) 21 (88)
) 4 (67) 15 (79) 18 (75)
) 2 (33) 12 (63) 16 (67)
1 (17) 3 (16) 7 (29)
Fig. 1 Schematic presentation of the experimental setup. Organ bath with the specimen containing KH solution at 37 °C and gassed continuously
with 5 % CO2 in oxygen. Changes in the tone of the preparations are recorded with electromechanical transducers and a potentiometric recorder
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contractile response to NA were included in the study.
After an equilibration period of 1 h, the experiment
started by repeating the NA and ACh administration.
After 1-h washout, the rings were incubated for 20 h in
KH solution at 37 °C with rapamycin 0.1, 1, and 10 μM
and ethanol in its highest concentration as solvent con-
trol. In each experiment, at least one ring served as a
time-matched control preparation to correct for any sen-
sitivity change. After 20 h, the rings were washed out,
the preload was readjusted to 1 g during a further equili-
bration period of 1 h before NA and ACh were tested
again.
Scanning electron microscopy
For scanning electron microscopy, 12 arterial rings from
four patients were carefully removed from the organ
holders after the in vitro experiments, fixed at 4 °C for
24 h in 2.5 % phosphate-buffered saline (PBS)-buffered
glutaraldehyde (pH 7.4, 300 mOsmol) and stored at 4 °
C in PBS buffer. The rings were cut longitudinally with a
razor blade, dehydrated and critical-point dried with li-
quid CO2. The specimens were mounted on stubs with
conductive silver paste, sputtered with 20 A gold in
argon atmosphere and examined in a Philips ESEM XL
30 scanning electron microscope at 20 kV (kilovolt).
Examination was performed by two independent ob-
servers in blinded fashion.
Western blotting on ITA homogenates
Samples of the ITA were splitted equally and incubated
in a six-well plate in RPMI containing 1 μM rapamycin
or solvent as control for 20 h. Before protein extraction
for Western blotting, the ITA segments were snap-frozen in liquid nitrogen and stored at −75 °C. The fro-
zen ITA rings were homogenized with a mortar, and
total protein was dissolved in lysis buffer (Ripa Sigma)
with protease and phosphatase inhibitors (Roche CPI).
Cell debris was removed by centrifugation, and superna-
tants were quantified by the protein assay, Precision Plus
Protein Standards (BioRad). Thereafter, 35 myg of total
protein was electrophoresed on two similar 10 % SDS-
polyacryl-amide gels and immunoblotted in a tank blot
onto polyvinylidene difluoride membranes (Life Tech-
nologies, TDE, Zug, CH). The membranes were probed
either with anti-Akt primary antibody (1:500) or with
anti-phospho-Akt Ser473 (1:500, Cell Signalling Tech-
nology) for 2 h at room temperature and then exposed
to horseradish peroxidase (HRP)-conjugated anti-rabbit
IgG (1:2000, Cell Signaling Technology). Probing against
mTOR was done either with a c-terminus-specific anti-
body (1:500, Sigma) or with a phospho-Ser2481-specific
antibody (1:1000, Cell signaling) overnight at 4 °C. For
standardization, glyceraldehyde 3-phosphate dehydro-
genase (GAPDH), detected with a monoclonal antibody
(1:1000, Sigma), was employed. For chemiluminescence,
a commercially available ECL-Substrate (Pierce, “Super-
Signal® West Pico Chemiluminescent Substrat”) was
used. Band density was measured with Quantity One
(BioRad) software and normalized to the GAPDH band
in the same lane by dividing the densities by the
GAPDH band density. Densitometric quantification was
performed as described above.
Western blotting on Hmec-1
Hmec-1 were cultivated in MCDB131 (Invitrogen) con-
taining 2 % FCS, 0.2 μg/ml hydrocortisone (Sigma), 10
ng/ml EGF (Sigma) and 100 μM ascorbic acid (Sigma).
Fig. 2 Relaxation of noradrenaline-precontracted ITA rings to
acetylcholine after exposure for 20 h to rapamycin (grey columns),
EtOH solvent (hatched column) and in time-matched controls (empty
column). Asterisk indicates significant difference to EtOH exposure.
For each column n = 8–10, bars represent SEM
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(Sigma R0278) including 1 % protease inhibitor cocktail
(Sigma P8340), 1 % phosphatase inhibitor cocktail 3
(Sigma P0044), 1 mM Na-orthovanadate and 10 mM
pyrophosphate. Thereafter, 30 μg protein of cell lysates
was separated by SDS-PAGE (7 % acrylamide gels) and
electrophoretically transferred to polyvinylidene fluoride
(PVDF) membranes (17 h, 150 mA). After transfer,
membranes were blocked with a caseine-based blocking
buffer (Sigma, B6429). For probing against protein phos-
phorylation on Ser1177 (p-eNOS), we used 1:1000 di-
luted SAB4300128 (Sigma) for 3 h at room temperature.
Antibodies against GAPDH (glycerinaldehyd-3-phos-
phat-dehydrogenase, Sigma, G9545) were used. For re-
action with a second antibody, peroxidase-conjugated
anti-rabbit antibodies (Sigma, A0545) were used. For
visualization of peroxidase signals, an enhanced lumi-
nescence protocol based on 1.25 mM luminol (Sigma,
A4685) in 100 mM Tris, pH 8.5, 0.6 mM p-coumaric
acid (Sigma, C9008) and 0.008 % hydrogen peroxide
(Sigma 216763,) was used. Densitometric quantification
was performed with “ImageJ” (ImageJ, java based, NIH,
MA, USA). In case of strong and inhomogeneous back-
ground, first profiles for each lane with Image J were
generated. Profile raw data were exported to Excel to
determine and calculate net peak areas. For normalization
of protein quantifications, the GAPDH signal which was
generated in a second probing step on the same mem-
branes was used.
Drugs used for functional studies
The following drugs were used: (−)-Noradrenaline
hydrogen tartrate, rapamycin (Sirolimus), (Fluka, Buchs,
Switzerland), and acetylcholine chloride (Dispersa A.G.,
Hettlingen, Switzerland).
Rapamycin was dissolved in ethanol and diluted in dis-
tilled water to give 1 ml solution/60 % ethanol.
Data analysis
Data analysis and graphic illustrations were made with
Origin software (Microcal Software Inc., Northampton,
MA, USA). Where appropriate, one-way analysis of
variance (ANOVA) was performed, followed by the
Bonferroni-corrected t test to assign differences to indi-
vidual between-group comparisons when overall signifi-
cance (P < 0.05) was attained. Data are presented as
mean values ± SEM.
Results and discussion
Functional activity
Preceding studies revealed that neither contractile re-
sponses to NA nor relaxant activity of acetylcholine
(ACh) was modified, when ITA rings had been exposed
for 20 min to rapamycin (10 nM–1 μM, not illustrated).Incubation for 20 h of ITA rings with rapamycin again
did not modify contractile responses to NA (1 μM);
however, endothelium-dependent relaxant responses to
ACh were significantly attenuated in a concentration-
dependent manner when ITA rings had been exposed
for 20 h to rapamycin (Fig. 2).
Scanning electron microscopy
Following 20-h exposure to rapamycin, the endothelial
layer was well preserved. There were no significant dif-
ferences between rapamycin-exposed and control rings.
Some spikes and blebs indicating cell cytoskeleton dam-
age could be noticed in both groups, but with the excep-
tion of a few spots, the integrity of the layer was
complete and intact (Fig. 3).
mTOR, Akt and eNOS phosphorylation in ITA
homogenates
When the effect of rapamycin was tested in homoge-
nates from ITA segments, a significant (p < 0.001) reduc-
tion of the protein phosphorylation on Ser473 (p-Akt)
indicated substantial down-regulation of Akt phosphoryl-
ation, whereas Akt protein levels remained unchanged
(p = 0.59, Fig. 4, right).
To investigate whether the signalling axis mTOR-Rictor
is involved in down-regulation of Akt-phosphorylation,
mTOR-phosphorylation and mTOR protein levels after
rapamycin treatment were analysed by Western blotting.
We focussed on Ser 2481 phosphorylation because this
site was recently reported to monitor mTOR signalling
Fig. 3 Representative scanning electron micrographs of the endothelium of human internal arteries after exposure to solvent (left) and after
exposure to 10 μM rapamycin (right) for 20 h taken from the same patient. Different magnifications are indicated by bars of 200, 100 and 50 μm
(from top to bottom). Some depositions of blood cells and noncellular material are seen in both groups. However, the endothelial layer is well
preserved in both groups, i.e. there were no differences between rapamycin-exposed and control rings
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cant reduction of the phospho-form of mTOR in extracts
of in vitro-treated ITA samples by 42.0 ± 10.8 % (p < 0.01,
n = 6) and a reduction by 77.3 ± 3.7 % (p < 0.005 n = 6) of
mTOR protein compared to corresponding controls
(Fig. 4, left).eNOS phosphorylation Hmec-1
Because of the low fraction of endothelial cells in human
arteries, the influence of rapamycin on eNOS activation
was investigated in the human endothelial cell line Hmec-
1. After 20-h incubation with rapamycin, a concentration-
dependent reduction of the phosphorylation on Ser1177
(p-eNOS) by 38.7 % (±6.8 % (SEM), p = 0.00116, n = 6;
10−8 M rapamycin), 42.8 % (±5.7 % (SEM), p = 0.00033,
n = 6; 10−7 M rapamycin) and 68.5 % (±7.7 % (SEM),
p = 0.00067, n = 5; 10−6 M rapamycin) indicating
substantial down-regulation of eNOS activity was
observed (Fig 5).Conclusions
Since sirolimus also known as rapamycin was discovered
as a product of the bacterium Streptomyces hygroscopi-
cus, it is used worldwide. The first sirolimus-eluting cor-
onary stent received CE Mark approval in Europe in
April 2002. Stent-induced restenosis involves a complex
interaction of biological events, endothelial injury and
injury due to lacerations of the arterial wall. Sirolimus is
known to have severe systemic adverse effects like can-
cerogenesis or lung toxicity. When used to prevent re-
stenosis, these concerning side effects should not be left
totally unconsidered.
Our aim was therefore to investigate in a human artery
setting if exposure of human internal thoracic arteries to
rapamycin in vitro modifies vascular function or nitric
oxide production, thus studying directly the physio-
logical and morphological influence of rapamycin on the
human endothelium.
The main finding of the present study is that incuba-
tion of human ITA in vitro for 20 h with rapamycin
Fig. 4 Left-hand traces. Top: Representative Western blot bands for phospho (Ser 2481)-mTOR (p-mTOR) and mTOR (anti-c-terminal antibody) on
internal thoracic artery tissue. Bottom: Columns indicate repression of p-mTOR and mTOR on ITA tissue exposed for 20 h to 1 μM rapamycin in
relation to controls (Ctl). Asterisk indicates statistical significance for down-regulation. Each test was performed and normalized in six experiments,
and the bars represent SEM. Right-hand traces. Top: Representative Western blot bands for phospho (Ser 473)-Akt (p-Akt) and Akt on internal
thoracic artery tissue. Bottom: Columns indicate changes of p-Akt (n = 24) and Akt (n = 19) in ITA tissue exposed for 20 h to 1 μM rapamycin in
relation to controls (Ctl). Asterisk indicates statistical significance for down-regulation, and the bars represent SEM
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ation in response to ACh in a concentration-dependent
manner. At the same time, Western blots of rapamycin-
treated human endothelial cell lines revealed a significant
concentration-dependent reduction of eNOS release. In
addition, Western blots of similarly incubated ITA ho-
mogenates showed a significantly reduced activation of
mTOR, p-mTOR and p-Akt while leaving Akt protein
levels unchanged, thus supporting the functional data.
The concentrations used in the present study are on
the low end compared to concentrations attained
in vivo, and it is likely that significantly higher local drug
concentrations are attained in arteries located in close
proximity to a drug-eluting stent because the lipophilic-
ity of rapamycin considerably enhances the uptake by
the arterial wall [12, 13]. Especially if serial stenting is
applied or multiple stents are used within the same cor-
onary system, e.g. left main stem, drug concentrations
may vary and reach significantly higher peak concentra-
tions in the downstream vessel. The present data thus
confirms clearly in vivo results from major clinical stud-
ies showing impaired endothelium-dependent relaxa-
tions in response to exercise or acetylcholine application
in coronary arteries distal to drug-eluting stents pointingto a cumulative downstream watershed impact of an
upstream-eluted drug compound. Patients with bare-
metal stents are not affected [10, 14]. However, in con-
trast to the functional effect of rapamycin in the present
study, electron microscopic examinations showed no
short-term effect of rapamycin exposure on vessel wall
morphology.
The mid-term and long-term effect of endothelial re-
newal, cell migration and cell composition under the in-
fluence of rapamycin is currently in focus of several
studies, and it is already known that mTOR regulates
vascular smooth muscle cell differentiation and plays an
important role in directing cell faith and endothelial
composition after intervention or vascular injury. With
mTOR being a central element in signalling pathways
involved in the control of cell growth and proliferation,
rapamycin also seems to affect the number, homing and
proliferation of endothelial progenitor cells resulting in
the prevention of endothelial healing [11–17].
Reduction of eNOS mRNA and protein expression by
rapamycin have been reported by several groups [18,
19]. Treatment of cultured human umbilical vein endo-
thelial cells with rapamycin increases Akt activity after
brief (up to 1 h) exposure while longer exposure (more
Fig. 5 Top: Representative Western blot bands for phospho (Ser 1177)-
eNOS (p-eNOS) in Hmec-1 after exposure to different concentrations of
rapamycin for 20 h in relation to controls (Ctl). Bottom: The columns
indicate activation of phospho-protein by eNOS after exposure to
different concentrations of rapamycin for 20 h in relation to controls
(Ctl). Each concentration was tested and normalized in five to six
experiments, and the bars represent SEM. Asterisk indicates significance
against controls
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determined by phosphorylation of its substrate glycogen
synthase kinase-3.
Protein-kinase B (PKB/Akt) normally mediates activa-
tion of eNOS, leading to increased NO production. How-
ever, rapamycin inhibits PKB/Akt via binding to mTOR
resulting in decreased NO production [20, 21]. In the
present experiments, a significant reduction of the protein
phosphorylation of p-mTOR and p-Akt in human ITA ho-
mogenates is in line with the functional data in ITA rings
suggesting that the rapamycin effect might occur via the
mTOR/Rictor pathway. Because of the low fraction of
endothelial cells in human ITA, the influence of rapamy-
cin on eNOS activation was investigated in the human
microvascular endothelial cell line Hmec-1. Accordingly,
after a 20-h incubation period of Hmec-1 with rapamycin,a significantly reduced concentration-dependent eNOS
phosphorylation was found.
These mechanisms explain the present observations
that rapamycin attenuated both function and NO pro-
duction/release by endothelial cells of ITA rings from a
representative population in vitro although scanning
electron microscopy did not show any acute structural
attenuation of the integrity of the endothelial layer be-
tween the groups at an early stage.
The most important stimulus for expanding the cor-
onary flow reserve is shear stress generated by streaming
blood along the endothelial layer. Thereby, continuous
formation of NO with a tremendous effect on coronary
vasodilation is induced. Shear stress stimulates phos-
phatidylinositol-3-OH-kinase (PIxK), activating Akt/PKB
by phosphorylation, which then phosphorylates eNOS pro-
tein, leading to an increased sensitivity to calcium. If so, it
is already active in producing NO at sub-physiological cal-
cium levels [22–24].
However, in the presence of rapamycin, vascular endo-
thelial growth factor, tumor necrosis factor and insulin
(like shear stress) failed to phosphorylate Akt/PKB, sup-
porting the contention that mTOR regulates Akt/PKB
activation in endothelial cells as reported .
In summary, we have demonstrated that incubation of
ITA in vitro for 20 h with rapamycin did not damage
endothelial cells histologically and that rapamycin atten-
uated both endothelial function in ITA rings and activa-
tion of eNOS in human endothelial cell lines in vitro.
Furthermore, it was found that exposure of ITA homog-
enates to rapamycin reduced activation of mTOR and p-
Akt suggesting that rapamycin inhibited eNOS in
endothelial cells in ITA via the mTOR/Rictor pathway.
Limitations
The current study can only mimic the pathophysio-
logical mechanisms leading to impaired coronary artery
function in a clinical setting after drug-eluting stent im-
plantation. The present experiments were performed on
ITA serving as an established human artery model. The
results are extrapolated to human coronary arteries
where the effects of rapamycin are obvious. As opposed
to the majority of existing data from animal studies,
these experiments were performed on human material
again emphasizing that marked species differences do
exist.
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